EPD:NYSEEnterprise Products Partners L.P. Analysis
Data as of 2026-03-31 - not real-time
$37.87
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Enterprise Products Partners is trading at a price of $37.87, comfortably above its 20‑day SMA of 37.72 and the 50‑day SMA of 36.10, while staying below the 200‑day SMA of 32.72, indicating a bullish technical backdrop. The MACD histogram is positive (0.01) and the signal line is bullish, the RSI sits at 54.6 and volume is on an upward trend, all pointing to continued short‑term momentum. Fundamental metrics show a P/E of 14.2 versus an industry average of 23.4, suggesting the stock is undervalued relative to peers, and the forward P/E of 12.2 adds further upside potential. Dividend yield remains attractive at 5.57% with a payout ratio of 81.2%, though free cash flow is thin, raising questions about long‑term sustainability. Recent analyst upgrades from Wells Fargo and Scotiabank, along with inclusion in high‑dividend lists, reinforce a positive sentiment and a modest upside of roughly 1.7% based on current support at 36.36 and resistance at 39.74. However, the company carries a high debt load (debt‑to‑equity > 110) and modest free cash flow, which temper the bullish outlook.
Overall, EPD presents a blend of value and income appeal: the stock is technically bullish, fundamentally cheap, and offers a high dividend, but investors should monitor leverage and cash‑flow sufficiency. The medium‑term horizon may see price pressure near the resistance level, while the long‑term case hinges on the company’s ability to service debt and maintain cash‑flow stability amid regulatory and sector‑specific risks.
Overall, EPD presents a blend of value and income appeal: the stock is technically bullish, fundamentally cheap, and offers a high dividend, but investors should monitor leverage and cash‑flow sufficiency. The medium‑term horizon may see price pressure near the resistance level, while the long‑term case hinges on the company’s ability to service debt and maintain cash‑flow stability amid regulatory and sector‑specific risks.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish technical indicators (MACD, RSI, rising volume)
- Analyst upgrades and positive sentiment
- Proximity to support level offering upside
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- High dividend yield offset by limited free cash flow
- Elevated debt-to-equity ratio increasing financial risk
- Potential price ceiling at resistance around $39.74
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued valuation relative to industry peers
- Stable contract‑based midstream cash flows
- Attractive dividend yield for income‑focused investors
Key Metrics & Analysis
Financial Health
Revenue Growth-2.90%
Profit Margin11.05%
P/E Ratio14.2
ROE19.50%
ROA5.61%
Debt/Equity113.94
P/B Ratio2.8
Op. Cash Flow$8.6B
Free Cash Flow$22.3M
Industry P/E23.4
Technical Analysis
TrendBullish
RSI54.6
Support$36.36
Resistance$39.74
MA 20$37.72
MA 50$36.10
MA 200$32.72
MACDBullish
VolumeIncreasing
Fear & Greed Index75.34
Valuation
Target Price$38.52
Upside/Downside1.73%
GradeUndervalued
TypeValue
Dividend Yield5.57%
Risk Assessment
Beta0.37
Volatility18.49%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.